BTGN Bitcoin Generation Inc (CE)

InoLife Technologies, Inc. (OTCBB:INOL), a service based healthcare products development, integration and marketing company, has appointed Wayne Erwin as Vice President of Business Development.

Mr. Erwin has more than 25 years of experience working in executive management roles at Fortune 500 companies, start-up government organizations, medical device companies, hospital systems and information technology. "I'm excited to be working with InoLife as the company continues to be a leader in the development of innovative DNA-based products," said Mr. Erwin. "With my knowledge of healthcare and overall DNA-based products, I look forward to being a part of the company's growth and success."  

Mr. Erwin is a former United States Army officer in the 101st Airborne Division and was the Chief Operating Officer and owner of Electronic Health Network, a leader in health care information technology. At Electronic Health Network, Mr. Erwin co-designed and developed the IT system architecture for a Health Information Exchange that electronically transfers physician/patient medical information between multiple, disparate health IT systems via a Virtual Private Network (VPN).

Prior to joining InoLife, Mr. Erwin was Chief Operating Officer at Crossroads Regional Hospital, a 100 bed, acute care, in-patient and outpatient psychiatric and substance abuse care facility in Alexandria, La. Mr. Erwin also served as Vice President of Sales in medical device, orthopedic, trauma/spine technology at Sulzer Corporation. While at Sulzer, Mr. Erwin increased sales revenues of new product introductions to $3.9 million.  

In addition, Mr. Erwin has extensive experience in DOD/DOE government contracting having worked for Texas Instruments, Ball Aerospace and ValleyLab, (Division of Pfizer), a medical-surgical product manufacturer.

"Wayne's extensive background in the healthcare and medical device arena combined with his expertise in company creation, technology development, sales and marketing and venture financing makes him a valuable addition," said Gary Berthold, CEO of InoLife. "We are confident that with Wayne as part of the company's management team, he will be a key component in the company's success in the development of future DNA-based products."

Mr. Erwin holds a Master's Degree and a Bachelor of Science Degree in biological sciences from Louisiana College.

About InoLife Technologies, Inc.

InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products.  Positioned for growth and success in a burgeoning market, InoLife Technologies, inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company's mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife's products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally, InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

Forward-Looking Statements

Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

CONTACT: Henry Harrison
         IR Pro 2.0, Inc.
         407-862-5151
         hharrison@insidewallstreet.com
         www.irprpro.com